HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target
10/15/2026
Impact: 80
Healthcare
HC Wainwright & Co. analyst Andres Y. Maldonado has reiterated a Buy rating on ImmunityBio (NASDAQ: IBRX) and maintained a price target of $15 for the stock. This reaffirms the firm's positive outlook on the company's performance.
AI summary, not financial advice
Share: